[1]许京华,李东升,李记天.健脾补肾中药对恶性骨肿瘤化疗后骨髓抑制患者外周血象的影响[J].中医正骨,2021,33(04):38-43.
　XU Jinghua,LI Dongsheng,LI Jitian.Effects of Jianpi Bushen(健脾补肾)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(04):38-43.
点击复制

健脾补肾中药对恶性骨肿瘤化疗后骨髓抑制患者外周血象的影响()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期数:
2021年04期
页码:
38-43
栏目:
临床研究
出版日期:
2021-04-20

文章信息/Info

Title:
Effects of Jianpi Bushen(健脾补肾)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors
作者:
许京华; 李东升; 李记天
(河南省洛阳正骨医院/河南省骨科医院,河南 郑州 450016)
Author(s):
XU Jinghua; LI Dongsheng; LI Jitian
Luoyang Orthopedic-Traumatological Hospital,Zhengzhou 450016,Henan,China
关键词:
骨肿瘤;  抗肿瘤联合化疗方案;  骨髓抑制;  健脾;  补肾;  中药疗法;  骨肉瘤;  肉瘤; Ewing;  组织细胞瘤; 恶性纤维;  转移癌
Keywords:
bone neoplasms;  antineoplastic combined chemotherapy protocols;  marrow suppression;  STRENGTHENING SPLEEN;  REINFORCING KIDNEY;  DRUG THERAPY(TCD);  osteosarcoma;  sarcoma; Ewing;  histiocytoma; malignant fibrous;  metastatic carcinoma
摘要:
目的:观察健脾补肾中药对恶性骨肿瘤化疗后骨髓抑制患者外周血象的影响。方法:将符合要求的60例恶性骨肿瘤化疗后骨髓抑制患者随机分为2组,每组30例。联合治疗组采用健脾补肾中药口服联合重组人粒细胞集落刺激因子皮下注射治疗,单纯西药组采用重组人粒细胞集落刺激因子皮下注射治疗; 均连续治疗7 d为1个疗程,共治疗1个疗程。比较2组患者治疗前后外周血液中白细胞计数、血红蛋白含量及血小板计数,并评估白细胞、血红蛋白及血小板抑制程度。治疗结束1周后,评价患者临床症状改善情况及生活质量。结果:①白细胞计数。治疗前2组患者的白细胞计数比较,差异无统计学意义[(3.28±0.64)×109个·L-1,(3.19±0.76)×109个·L-1,t=0.566,P=0.576]; 治疗结束1周后,2组患者的白细胞计数均高于治疗前(t=-6.606,P=0.000; t=-3.583,P=0.000),且联合治疗组患者的白细胞计数高于单纯西药组[(8.68±1.75)×109个·L-1,(4.63±1.20)×109个·L-1,t=10.954,P=0.000]。②血红蛋白含量。治疗前2组患者的血红蛋白含量比较,差异无统计学意义[(112.47±10.05)g·L-1,(108.63±9.67)g·L-1,t=-1.941,P=0.062]; 治疗结束1周后,2组患者的血红蛋白含量均高于治疗前(t=-11.750,P=0.000; t=-5.695,P=0.000),且联合治疗组患者的血红蛋白含量高于单纯西药组[(140.83±17.36)g·L-1,(126.87±15.56)g·L-1,t=4.331,P=0.000]。③血小板计数。治疗前2组患者的血小板计数比较,差异无统计学意义[(121.10±23.51)×109个·L-1,(126.90±30.52)×109个·L-1,t=-1.250,P=0.221]; 治疗结束1周后,2组患者的血小板计数均高于治疗前(t=-12.528,P=0.000; t=-5.846,P=0.000),且联合治疗组患者的血小板计数高于单纯西药组[(224.23±60.28)×109个·L-1,(187.70±55.89)×109个·L-1,t=2.741,P=0.010]。④白细胞抑制程度。治疗结束1周后,联合治疗组0度9例、Ⅰ度11例、Ⅱ度7例、Ⅲ度3例,单纯西药组0度4例、Ⅰ度7例、Ⅱ度8例、Ⅲ度6例、Ⅳ度5例; 联合治疗组患者的白细胞抑制程度优于单纯西药组(Z=-2.717,P=0.007)。⑤血红蛋白抑制程度。治疗结束1周后,联合治疗组0度8例、Ⅰ度10例、Ⅱ度12例,单纯西药组0度3例、Ⅰ度10例、Ⅱ度6例、Ⅲ度6例、Ⅳ度5例; 联合治疗组患者的血红蛋白抑制程度优于单纯西药组(Z=-2.547,P=0.011)。⑥血小板抑制程度。治疗结束1周后,联合治疗组0度11例、Ⅰ度13例、Ⅱ度4例、Ⅲ度2例,单纯西药组0度8例、Ⅰ度7例、Ⅱ度8例、Ⅲ度4例、Ⅳ度3例; 联合治疗组患者的血小板抑制程度优于单纯西药组(Z=-2.009,P=0.045)。⑦临床症状改善情况。治疗结束1周后,联合治疗组显著改善13例、部分改善14例、无效3例,单纯西药组显著改善7例、部分改善12例、无效11例; 联合治疗组患者的临床症状改善情况优于单纯西药组(Z=-2.363,P=0.018)。⑧生活质量。治疗结束1周后,联合治疗组改善16例、稳定10例、降低4例,单纯西药组改善9例、稳定8例、降低13例; 联合治疗组患者的生活质量高于单纯西药组(Z=-2.430,P=0.015)。⑨其他。治疗过程中,单纯西药组6例应用促红细胞生成素、3例输注血小板,联合治疗组无1例采取上述措施。结论:对于恶性骨肿瘤化疗后骨髓抑制患者,在采用重组人粒细胞集落刺激因子皮下注射治疗的基础上,应用健脾补肾中药口服治疗,可以增加外周血液中白细胞计数、血红蛋白含量及血小板计数,减轻骨髓抑制程度,有利于改善临床症状、提高生活质量,其疗效优于单纯采用重组人粒细胞集落刺激因子皮下注射治疗。
Abstract:
To observe the effects of Jianpi Bushen(健脾补肾,JPBS)traditional Chinese medicine(TCM)on peripheral hemogram of patients with myelosuppression after chemotherapy for treatment of malignant bone tumors.Methods:Sixty patients with myelosuppression after chemotherapy for malignant bone tumors were enrolled in the study and were randomly divided into 2 groups,30 cases in each group.The patients were treated with combination therapy of subcutaneous injection of recombinant human granulocyte colony-stimulating factor(rhG-CSF)and oral application of JPBS TCM(combination therapy group)and monotherapy of subcutaneous injection of rhG-CSF(monotherapy group)respectively for one course of treatment,consecutive 7 days for each course.The white blood cell(WBC)counts,hemoglobin(HGB)contents and platelet counts in peripheral blood were recorded and compared between pretreatment and posttreatment and between the 2 groups,and the inhibition degrees of WBC,HGB and platelet were evaluated.Moreover,the improvement of clinical symptoms and life quality of patients in the 2 groups were evaluated at 1 week after the end of the treatment.Results:There was no statistical difference in WBC counts between the 2 groups before the treatment(3.28±0.64 vs 3.19±0.76 ×10(9)cells/L,t=0.566,P=0.576).The WBC counts were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-6.606,P=0.000; t=-3.583,P=0.000),and were higher in combination therapy group compared to monotherapy group(8.68±1.75 vs 4.63±1.20 ×10(9)cells/L,t=10.954,P=0.000).There was no statistical difference in HGB contents between the 2 groups before the treatment(112.47±10.05 vs 108.63±9.67 g/L,t=-1.941,P=0.062).The HGB contents were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-11.750,P=0.000; t=-5.695,P=0.000),and were higher in combination therapy group compared to monotherapy group(140.83±17.36 vs 126.87±15.56 g/L,t=4.331,P=0.000)...

参考文献/References:

[1] 张剑峰,刘宽荣.骨恶性肿瘤36例手术治疗临床分析[J].山西医药杂志,2015,44(1):80-82.
[2] 李建强,孙虹斐,靳宇,等.补肾益精汤联合化疗预防肿瘤患者骨髓抑制的作用及对血清G-CSF、IL-3水平的影响[J].现代中西医结合杂志,2017,26(33):3708-3710.
[3] 王和鸣,黄桂成.中医骨伤科学[M].3版.北京:中国中医药出版社,2012:377-378.
[4] 丁聚贤,谢兴文,许伟,等.中医药在骨肉瘤放化疗中的作用研究进展[J].中医正骨,2018,30(5):43-46.
[5] 中华医学会骨科学分会骨肿瘤学组.四肢骨肿瘤保肢治疗指南[J].中华骨科杂志,2019,39(1):1-9.
[6] 周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2003:537-555.
[7] 周仲瑛.中医内科学[M].北京:中国中医药出版社,2017:120-125.
[8] SCHAG C C,HEINRICH R L,GANZ P A.Karnofsky performance status revisited:reliability,and guidelines[J].J Clin Oncol,1984,2(3):187-193.
[9] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[10] CHOI Y Y,KIM J Y,YANG S O.PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions[J].Semin Musculoskelet Radiol,2014,18(2):133-148.
[11] NIU X,XU H,INWARDS C Y,et al.Primary bone tumors:epidemio-logic comparison of 9200 patients treated at Beijing Ji Shui Tan Hospital,Beijing,China,with 10165 patients at Mayo Clinic,Rochester,Minnesota[J].Arch Pathol Lab Med,2015,139(9):1149-1155.
[12] 刘宏杰,张宁,李凌云,等.甲磺酸阿帕替尼三线及以上治疗晚期恶性肿瘤52例疗效观察[J].皖南医学院学报,2020,39(3):242-245.
[13] 赵秀兰,张星星,郑寰宇,等.HIF相关信号转导通路因子在宫颈癌中的研究进展[J].河北医科大学学报,2018,39(11):1360-1364.
[14] 王国华,刘凤玲,张振山,等.参一胶囊联合化疗治疗晚期非小细胞肺癌疗效观察与血清MMP-9及TIMP-1变化[J].现代肿瘤医学,2017,25(6):896-901.
[15] 元建华,李建旺,张曙波,等.吉西他滨联合替吉奥治疗铂类方案化疗失败晚期鼻咽癌患者临床观察[J].中华肿瘤防治杂志,2019,26(3):170-174.
[16] HOU B,LIU R,QIN Z,et al.Oral Chinese herbal Medicine as an adjuvant treatment forchemotherapy,or radiotherapy,induced myelosuppression:a systematic review and Meta analysis of randomized controlled trials[J].Evid Based Complement Alternat Med,2017,2017(5):1-13.
[17] 顾玉兰.粒细胞集落刺激因子在化疗患者中的应用调查[J].中国癌症防治杂志,2014,6(2):177-180.
[18] 陈丹,陈理.中医药防治化疗后骨髓抑制的研究进展[J].江苏中医药,2012,44(7):76-77.
[19] 章伟,赵林林,陈立伟,等.恶性肿瘤化疗后骨髓抑制的中医药防治进展[J].四川中医,2014,32(6):179-182.
[20] 侯天将,尚静,由凤鸣,等.化疗所致骨髓抑制的中医病机要素及临床治疗分析[J].云南中医中药杂志,2016,37(9):31-33.
[21] 王茜,窦永起.化疗后骨髓抑制的中药防治研究进展[J].现代医药卫生,2013,29(14):2141-2143.
[22] 陶灵佳,任建琳,季青,等.健脾补肾复方治疗大肠癌靶点的网络药理学研究[J].中华中医药杂志,2017,32(4):1772-1774.
[23] 孙政华,邵晶,郭玫.党参化学成分及药理作用研究进展[J].安徽农业科学,2015,43(33):174-176.
[24] 刘爽.黄芪药理作用的研究进展[J].北方药学,2015,12(12):95-96.
[25] 刘医辉,杨世英,马伟林,等.当归药理作用的研究进展[J].中国当代医药,2014,21(22):192-193.
[26] 祝烨.人参、黄芪、当归对血发生的影响[J].成都中医药大学学报,2000,23(3):55-56.
[27] 芮鑫淼,钱佳诚,李永峰,等.健脾补肾法治疗放化疗后骨髓抑制研究进展[J].浙江中西医结合杂志,2019,29(7):606-608.

相似文献/References:

[1]朱丽英,胡春艳,孟苗,等.唑来膦酸静脉滴注联合华蟾素胶囊口服治疗转移性骨肿瘤[J].中医正骨,2017,29(07):55.
[2]易春智,蓝鋆,李若愚,等.冷冻消融术在骨与软组织肿瘤治疗中的应用[J].中医正骨,2017,29(09):57.
[3]忻岳军,陈天亮,尹彬彬.基于CT周围神经重建图像判断骨和软组织肿瘤与邻近神经的关系[J].中医正骨,2021,33(10):41.

更新日期/Last Update: 1900-01-01